Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-021496
Filing Date
2025-02-14
Accepted
2025-02-14 17:27:29
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5479
  Complete submission text file 0000950170-25-021496.txt   6926
Mailing Address 444 WEST LAKE STREET, SUITE 1700 CHICAGO IL 60606
Business Address 444 WEST LAKE STREET, SUITE 1700 CHICAGO IL 60606 312-416-8592
MAIA Biotechnology, Inc. (Subject) CIK: 0001878313 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-93731 | Film No.: 25631167
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 444 WEST LAKE STREET, SUITE 1700 CHICAGO IL 60606
Business Address
Gryaznov Sergei (Filed by) CIK: 0001913228 (see all company filings)

Type: SCHEDULE 13G/A